earticle

영어

Plants and plant cells are evolving with improved safety and production as attractive options for biopharmaceutical production. A significant barrier to the development of biopharmaceuticals in plants, however, lies in the fact that plant-derived N-glycans contain plant-specific sugar residues such as β1,2-xylose and α1,3-fucose bound to the pentasaccharide core (Man3GlcNAc2) as well as β1,3-galactose and α1,4-fucose involved in the formation of Lewis a (Lea) epitope that may cause allergic reactions in humans. Additionally, sugar residues such as α1,6-fucose, β1,4-galactose, and α2,6-sialic acid, which are believed to play important roles in biopharmaceutical action, storage, distribution, and half-life, are missing from the naturally occurring N-glycans in plants. To use plant cells as a means of producing biopharmaceuticals, it is essential to produce plants which contain N-glycan compatible with biopharmaceuticals. However, the structure of N-glycans appears to be related to hormone signalling and how the structure of N-glycans altered during glycoengineering influences plant production is still uncertain. Here, we suggest a strategy for producing customized N-glycans in plants and the related technological barriers.